 |
|
|
| |
Similar Efficacy and Safety By Subgroup in DRIVE-AHEAD: DOR/3TC/TDF vs EFV/FTC/TDF
|
| |
| |
Reported by Jules Levin
CROI 2018 March 4-7 Boston MA
Chloe Orkin1; Kathleen E. Squires2,8; Jean-Michel Molina3; Paul E. Sax4; Wing-Wai Wong5; Otto Sussmann6; Richard Kaplan7; Anthony Rodgers8; Xia Xu8; Gina Lin8; Sushma Kumar8; George J. Hanna8; Carey Hwang8; Elizabeth Martin8 for the DRIVE-AHEAD Study Group
1Royal London Hospital, London, UK; 2Thomas Jefferson University, Philadelphia, PA, USA; 3Universite Paris Diderot, Hôpital Saint-Louis, Paris, France; 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; 5Taipei Veterans General Hospital, Taipei, Taiwan; 6Asistencia Cientifica de Alta Complejidad SAS, Bogotá, Colombia; 7Desmond Tutu HIV Foundation, Cape Town, South Africa; 8Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
